Asset Plus Property Valuations

GENERAL
Fri, Apr 05 2024 09:30 am

NZX release
Asset Plus Property Valuations
5 April 2024

Asset Plus (NZX: APL) advises that it expects a reduction in fair value of Munroe Lane for the six months ended 31 March 2024 of $2.5m, being a 2.1% decrease.

Munroe Lane has been independently valued and has reduced in value from $120.0m to $116.2m. The main driver of this change is the unleased space at the property with an increase in the associated incentives and letting up period. The expected fair value as at 31 March 2024 is forecast to be $115.8m reflecting the independent valuation less the remaining balance of costs associated with the development of $0.4m.

The 35 Graham Street fair value increases by a further $2.2m across the past six months reflecting the impact of the discount unwind.

The combined impact of the above fair value movements represents a forecast 0.3 cents per share reduction in the NTA to 38.8 cents per share.

The independent valuation, forecast valuation movements and forecast reduction in NTA remain subject to external audit review and will be confirmed in APL’s consolidated financial statements which are expected to be released on 28 May 2024.

-ENDS-

For further information, please contact:

Stephen Brown-Thomas
Asset Plus Fund Manager, Centuria NZ, manager of Asset Plus Limited
+64 9 300 6161

Simon Woollams
Asset Plus CFO, Centuria NZ, manager of Asset Plus Limited
+64 9 300 6161




Announcement PDF


Markets News

NZ sharemarket down, Oz and US stocks climb
Markets Market close

NZ sharemarket down, Oz and US stocks climb

The S&P/NZX 50 Index closed at 11,746.66, down 44.26 points or 0.38%.

Graham Skellern 04 Jul 2024
Markets

Summerset anticipates flat 1H underlying profit

The company is NZ's best-performing retirement village operator.

Gregor Thompson 04 Jul 2024
Summerset anticipates flat 1H underlying profit
Markets

Infratil's CDC investment cracks $5 billion mark

Surging datacentre demand and expanded development plans benefit Infratil.

Infratil's CDC investment cracks $5 billion mark